Our study also highlights the clinical relevance and prognostic significance of SHMT2-dependent regulation of β-catenin, indicating that the assessment of SHMT2, in conjunction with β-catenin, may provide a more detailed understanding of malignant risk for individual CRC patients. The gene discussed is SHMT2; the disease is colorectal carcinoma.